Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-08-16, Stock:NVS, The news for the past five days is as follows:
2019-08-09: NEWS1: Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?.NEWS2: Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?.NEWS3: Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2.NEWS4: Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2.NEWS5: Has Novartis (NVS) Outpaced Other Medical Stocks This Year?.NEWS6: Has Novartis (NVS) Outpaced Other Medical Stocks This Year?.NEWS7: Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2.NEWS8: Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?.NEWS9: Has Novartis (NVS) Outpaced Other Medical Stocks This Year?.
2019-08-12: NEWS1: UPDATE 1-Senator Grassley seeks info on Novartis's Zolgensma data issues.NEWS2: Senator Grassley seeks info on Novartis's Zolgensma data issues.NEWS3: The Biggest Biotech Stock Is Approaching A Breakout — Here's Why.NEWS4: Amgen wins U.S. patent battle on arthritis drug Enbrel.NEWS5: Amgen stock gets boost from Friday ruling on Enbrel.NEWS6: Amgen Wins Enbrel U.S. Patent Litigation Against Novartis.NEWS7: Amgen Wins Enbrel U.S. Patent Litigation Against Novartis.NEWS8: Amgen Wins Enbrel U.S. Patent Litigation Against Novartis.NEWS9: Amgen’s Court Win Could Mark ‘a New Dawn’ for the Stock.NEWS10: [video]Amgen Climbs After Winning Patent Case on Enbrel.NEWS11: Amgen Climbs After Winning Patent Case on Enbrel.NEWS12: 5 Big Pharma Showdowns to Watch.
2019-08-13: NEWS1: Why This IBD Stock Of The Day Is No Longer Sweating $5 Billion In Sales.NEWS2: Here's Why Amgen Stock is Outperforming Its Industry Of Late.NEWS3: Here's Why Amgen Stock is Outperforming Its Industry Of Late.NEWS4: Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate.NEWS5: Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate.NEWS6: Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate.NEWS7: Here's Why Amgen Stock is Outperforming Its Industry Of Late.NEWS8: Pre-Market Most Active for Aug 13, 2019 :  JD, UBS, DCPH, TVIX, NVS, GE, AMD, SQQQ, QQQ, TME, BABA, BE.NEWS9: Pre-Market Most Active for Aug 13, 2019 :  JD, UBS, DCPH, TVIX, NVS, GE, AMD, SQQQ, QQQ, TME, BABA, BE.NEWS10: 5 Biggest New Drugs Approved in 2019 So Far.NEWS11: 5 Biggest New Drugs Approved in 2019 So Far.NEWS12: 5 Biggest New Drugs Approved in 2019 So Far.
2019-08-14: NEWS1: Novartis Reportedly Fires Brothers For Manipulating Gene Therapy Data.NEWS2: Wednesday’s Vital Data: Amgen, American Airlines and Apple.NEWS3: Wednesday’s Vital Data: Amgen, American Airlines and Apple.NEWS4: Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%.NEWS5: Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%.NEWS6: Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study.NEWS7: Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study.NEWS8: UPDATE 2-Novartis replaces top scientists at Avexis after drug data manipulated.NEWS9: Everyone’s Mad At Novartis. But the Stock Is Doing Just Fine.NEWS10: Novartis replaces top scientists at Avexis after drug data manipulated.NEWS11: Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%.NEWS12: Wednesday’s Vital Data: Amgen, American Airlines and Apple.NEWS13: Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study.NEWS14: Novartis names Bulto as new head of U.S. drugs business.NEWS15: Novartis ousted scientists before reporting drug data manipulation.
2019-08-15: NEWS1: Frozen assets: How a startup wants to cryobank your cells to fight cancer in the future.NEWS2: Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat.NEWS3: Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat.NEWS4: Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat.NEWS5: Novartis replaces top scientists at Avexis after drug data manipulated.NEWS6: PRESS DIGEST- Financial Times - Aug 15.

Answer: Rise